FibroGen Q3 loss of $91.7M; China roxadustat revenue up 29% YoY to $17.4M

KYNTRA BIO, INC.

2022-Q3 EPS reported -$2.43 revenue$106,367,000

Total revenue $15.7M vs $156.0M in Q3 2021, which included $120M Astellas milestone
Net loss $91.7M ($0.98/sh) vs net income $49.8M ($0.54/sh) year ago
China roxadustat net sales $59.0M (incl. JDE); volume growth >80% vs Q3 2021
Completed MATTERHORN Phase 3 enrollment; topline data expected 1H 2023
Non-dilutive royalty monetization with NovaQuest provides $50M; cash target $380-410M YE 2022

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

KYNTRA BIO, INC. reported the third quarter 2022 results: revenue $15.7 million, net income Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share, EPS $0.98 net loss per basic and diluted share.

Period: the third quarter 2022
Revenue: $15.7 million
Net income: Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share
EPS: $0.98 net loss per basic and diluted share
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2022 was $15.7 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-022593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.